Lori Lyons-Williams
CIK 1693564 · Chief Commercial Officer · last filed 2026-06-26
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$170.5K
Companies
5
Total Filings
20
Lifetime Open-Market Net
$0
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CTNM | Director | — | $14.82 | — | $0 | 3 | 2026-06-26 |
| RAPT Therapeutics, Inc. (RAPT) Delisted | Director | 4,956 | $58.01 | $287.5K | $0 | 6 | 2026-02-02 |
| FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Director | — | $38.00 | — | $0 | 2 | 2021-04-19 |
| DERM | Chief Commercial Officer | 26,983 | $6.32 | $170.5K | $0 | 6 | 2019-08-19 |
| FIVE PRIME THERAPEUTICS, INC. (XLRN) Delisted | Director | — | $178.75 | — | $0 | 1 | 2019-06-25 |
Recent Filings · Page 2 of 2
20 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-04-19 | FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Disp (D) | — | $0 | EDGAR |
| 2020-05-15 | FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-02-24 | — | Disp (D) | −25,401 | -$476.3K | |
| 2019-08-19 | DERM | Mixed | +1,607 | -$12.5K | EDGAR |
| 2019-06-25 | FIVE PRIME THERAPEUTICS, INC. (XLRN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-05-21 | DERM | Mixed | +19,626 | -$108.9K | EDGAR |
| 2019-02-14 | DERM | Grant (A) | — | $0 | EDGAR |
| 2018-08-17 | DERM | Mixed | +695 | -$3.5K | EDGAR |
| 2018-02-16 | DERM | Grant (A) | — | $0 | EDGAR |
| 2017-01-10 | DERM | Grant (A) | — | $0 | EDGAR |
Showing 11–20 of 20
Prev
Page 2 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.